|Bid||1.1700 x 45900|
|Ask||1.2000 x 800|
|Day's Range||1.1100 - 1.2900|
|52 Week Range||0.6400 - 4.4800|
|Beta (5Y Monthly)||1.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2022 - Mar 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.14|
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shareholders (or potential shareholders) will be happy to see that the...
Regulatory and other updates from bluebird (BLUE) and Rigel (RIGL) are a few key highlights from the biotech sector during the past week.
Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.